Study to investigate multiple ascending oral doses of AZD5213 in Healthy Male and non fertile Female Subjects
Study identifier:D3030C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Double-blind, Randomized, Placebo-controlled', Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD5213 After Administration of Multiple Ascending Doses for 10 Days in Healthy Male and Non-fertile Female Volunteers
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD5213, Placebo to AZD5213
Sex
All
Actual Enrollment
73
Study type
Interventional
Age
18 Years - 80 Years
Date
Study Start Date: 01 Jul 2010
Primary Completion Date: 01 May 2011
Study Completion Date: 01 May 2011
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 AZD5213 (dose escalating) | Drug: AZD5213 oral solution, multiple ascending doses |
| Placebo Comparator: 2 Placebo | - |
Contacts
Investigators
Principal Investigator
David Mathews, MD
Quintiles, 6700 W. 115th Street, Overland Park, KS 66211
